Posted by Michael Wonder on 16 Apr 2018
ICER's final report on emicizumab shows new treatment improves health while lowering costs for certain people with haemophilia A
16 April 2018 - Report also highlights need for future pricing of haemophilia treatments that allows for "shared savings" between innovators and society.
The Institute for Clinical and Economic Review today released a final evidence report and report-at-a-glance on emicizumab (Hemlibra, Genentech) for the prevention of bleeds (prophylaxis) in a subset of individuals with haemophilia A who have inhibitors to the clotting protein Factor VIII.
ICER’s report was reviewed at a public meeting of the New England Comparative Effectiveness Public Advisory Council (New England CEPAC), where a majority of the Council voted that evidence suggests a net health benefit of emicizumab compared to either no prophylaxis or prophylaxis with bypassing agents, therapies commonly used in patients with inhibitors. The Council also emphasised the drug’s benefits beyond those captured in clinical trials, including simpler therapy administration, reduced caregiver burden, and patients’ increased ability to participate in work, school, or other activities.
